Drug Trial Radar · NCT05061550
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
630
Planned (sponsor's estimate)
Start
Apr 14, 2022
Primary completion
May 28, 2030
Study completion May 28, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Sep 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Conditions
- Non-small Cell Lung Cancer
Interventions
DurvalumabDrug
Participants will receive Durvalumab via intravenous route.
OleclumabDrug
Participants will receive Oleclumab via intravenous route.
MonalizumabDrug
Participants will receive Monalizumab via intravenous route.
Dato-DXdDrug
Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
AZD0171Drug
Participants will receive AZD0171 via intravenous route.
CarboplatinDrug
Carboplatin as chemotherapy
CisplatinDrug
Cisplatin as chemotherapy
Pemetrexed/CisplatinDrug
Pemetrexed/Cisplatin as chemotherapy
Pemetrexed/CarboplatinDrug
Pemetrexed/Carboplatin as chemotherapy
Carboplatin/PaclitaxelDrug
Carboplatin/Paclitaxel, as chemotherapy
VolrustomigDrug
Participants will receive Volrustomig via intravenous route.
RilvegostomigDrug
Participants will receive Rilvegostomig via intravenous route.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with pathological complete response (pCR)Time frame: From randomization to approximately 15 weeks after the first dose of study interventions
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Until Day 90 after the last dose of study interventions (Up to approximately 3 years)
Locations
97 sites in 12 countries. Site status is shown where the registry gives one.
Research Site
Little Rock, Arkansas · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Oakland, California · Withdrawn
Research Site
New Haven, Connecticut · Recruiting
Research Site
Stuart, Florida · Completed
Research Site
Gainesville, Georgia · Withdrawn
Research Site
Chicago, Illinois · Recruiting
Research Site
Baltimore, Maryland · Withdrawn
Research Site
Baltimore, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Saint Louis Park, Minnesota · Completed
Research Site
Omaha, Nebraska · Recruiting
Research Site
Buffalo, New York · Withdrawn
Research Site
Cleveland, Ohio · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Chattanooga, Tennessee · Recruiting
Research Site
Memphis, Tennessee · Recruiting
Research Site
Nashville, Tennessee · Withdrawn
Research Site
Nashville, Tennessee · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Houston, Texas · Terminated
Research Site
Fairfax, Virginia · Recruiting
Research Site
Edmonds, Washington · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Ghent, Belgium · Recruiting
Research Site
Ghent, Belgium · Completed
Research Site
Roeselare, Belgium · Recruiting
Research Site
Edmonton, Alberta, Canada · Completed
Research Site
Winnipeg, Manitoba, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Avignon, France · Recruiting
Research Site
Bobigny, France · Withdrawn
Research Site
Bordeaux, France · Recruiting
Research Site
Limoges, France · Recruiting
Research Site
Rennes, France · Recruiting
Research Site
Rouen, France · Recruiting
Research Site
Suresnes, France · Recruiting
Research Site
Toulon, France · Active not recruiting
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.